Nivolumab (Opdivo®) for non-squamous NSCLC

Assessment Status Assessment Process Complete
Drug Nivolumab
Brand Opdivo®
Indication Is indicated for the treatment of adults with locally advanced or metastatic non-squamous NSCLC after prior chemotherapy.
Assessment Process
Rapid review commissioned 03/03/2016
Rapid review completed 04/04/2016
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 27/04/2016
NCPE assessment completed 12/10/2016
NCPE assessment outcome Reimbursement Not Recommended at the Submitted Price.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations September 2018